small molecule

COLCRYS

COLCHICINE

Loss of exclusivityFebruary 2029latest FDA-listed patent expiry
CompanyTAKEDA PHARMACEUTICALS USA INC

Drug detail

Brand nameCOLCRYS
Active ingredientCOLCHICINE
Strength0.6MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalJuly 2009
Marketing statusDISCN

Listed patents

PatentExpiresType
8440722February 2029use U-1020
7820681February 2029use U-1020
7915269February 2029use U-1007
8440721February 2029use U-1007
7906519February 2029use U-1116
7601758February 2029use U-1007
7619004December 2028use U-1020
7935731December 2028use U-1116
8097655October 2028use U-1020
8093297October 2028use U-1161
7964648October 2028use U-1161
8093296October 2028use U-1007
8093298October 2028use U-1116
8415395October 2028use U-1007
7964647October 2028use U-1007
7981938October 2028use U-1166
8415396October 2028use U-1007

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

COLCRYS patent cliff — loss of exclusivity February 2029 | CliffBio